2026-06-23

Silver volume spike — 616.9× the 20-day average (58,216 vs 94 avg)

Gold volume spike — 18.4× the 20-day average (115,842 vs 6,311 avg)

Copper volume spike — 49.0× the 20-day average (53,037 vs 1,081 avg)

Platinum volume spike — 1475.6× the 20-day average (18,562 vs 12 avg)

Corn bull 6.4% vs prior close ($411.50 → $437.75)

OSINT: US Air Force Deploys 9 Refueling Aircraft Over Strait of Hormuz

CFTC COPPER speculators at extreme long: 52-week positioning extreme

CFTC NATURAL GAS speculators at extreme long: 52-week positioning extreme

CFTC BITCOIN speculators at extreme long: 52-week positioning extreme

OSINT: Trump says Strait of Hormuz will stay open, 19M barrels flow record

CFTC COPPER speculators at extreme long: 52-week positioning extreme

CFTC NATURAL GAS speculators at extreme long: 52-week positioning extreme

CFTC BITCOIN speculators at extreme long: 52-week positioning extreme

OSINT: Russian stocks dip at open on June 23

CFTC SILVER speculators at extreme short: 52-week positioning extreme

CFTC NATURAL GAS speculators at extreme long: 52-week positioning extreme

CFTC BITCOIN speculators at extreme long: 52-week positioning extreme

OSINT: Russian waste-processing investments plunge sixfold to 12.6 bn rubles

CFTC SILVER speculators at extreme short: 52-week positioning extreme

CFTC NATURAL GAS speculators at extreme long: 52-week positioning extreme

CFTC BITCOIN speculators at extreme long: 52-week positioning extreme

OSINT: Ukrainian drones strike Russian missile depot in Crimea, trigger big blast

Oil -2.41%: significant decline on the session

Cotton bull 4.4% vs prior close ($75.21 → $78.50)

Silver bear 5.9% vs prior close ($65.53 → $61.63)

RBOB Gasoline bear 4.8% vs prior close ($2.99 → $2.84)

Sugar No. 11 bull 4.3% vs prior close ($13.35 → $13.93)

OSINT: US Senate backs bill to halt US military action against Iran

Gold -1.01%: significant decline on the session

Oil -2.41%: significant decline on the session

BTC ETF outflow of $2218M — institutional selling

ETH ETF outflow of $190M — institutional selling

SOL open interest -32.5% — OI collapse

BTC open interest +60.2% — OI surge

ETH open interest -68.8% — OI collapse

SOL open interest -58.8% — OI collapse

ETH open interest -66.4% — OI collapse

BTC open interest +94.6% — OI surge

SOL open interest +39.2% — OI surge

ETH open interest -68.2% — OI collapse

BTC open interest +100.5% — OI surge

SOL open interest +39.3% — OI surge

ETH open interest -67.7% — OI collapse

BTC open interest -40.7% — OI collapse

OSINT: Nvidia market cap slips below $5 trillion as shares tumble 4%

OSINT: Fed December Rate Hike Odds Surge to 77%

SOL DEX volume/liquidity ratio elevated (0.89x): on-chain trade volume 0.89x liquidity

OSINT: Oobit Links USDT to Brazil’s Pix, Unlocking Crypto Payments for 170M Users

OSINT: US Senate bans Fed CBDC until 2030, protects private stablecoins

OSINT: US Treasury sanctions 9 individuals, 26 entities in SE Asian crypto fraud scheme

Phase 3 trial terminated early — JOHNSON A Study Evaluating Epoetin Alfa 40,000 IU (International Units) Every Week or 80

Phase 3 trial terminated early — JOHNSON A Study of the Effectiveness and Safety of Tramadol HCl/Acetaminophen Compared t

Phase 3 trial terminated early — JOHNSON A Long-term Safety Study With Tapentadol ER and Oxycodone CR in Patients With Mo

Phase 3 trial terminated early — ELI An Open Label Study for Participants With Rheumatoid Arthritis

Phase 3 trial terminated early — ELI A Long-Term, Open-Label, Study on Schizophrenia

Phase 3 trial terminated early — ELI ERCC1 Targeted Trial

Phase 3 trial terminated early — BRISTOL FOLFIRI or FOLFOX With or Without Cetuximab in Patients With Metastatic Adenocar

Phase 3 trial terminated early — BIOGEN Safety and Efficacy of Zevalin in the Treatment of Non-Hodgkin's Lymphoma

Phase 3 trial terminated early — AMGEN Study to Assess Darbepoetin Alfa Dosing for the Correction of Anemia in Pediatri

Phase 3 trial terminated early — AMGEN Efficacy and Safety of Cinacalcet in Pediatric Patients With Secondary Hyperpara

Phase 3 trial terminated early — AMGEN Denosumab in Primary Hyperparathyroidism

Phase 3 trial terminated early — INCYTE Nivolumab and Epacadostat With Platinum Doublet Chemotherapy Versus Platinum Dou

Phase 3 trial terminated early — Medtronic Endovascular Revascularization With Solitaire Device Versus Best Medical Therapy

Phase 3 trial terminated early — Medtronic EnTRINSIC - EnPulse Trial on Search AV+ Influence

Phase 3 trial terminated early — Merck Efficacy and Safety Trial of Verubecestat (MK-8931) in Participants With Prodrom

Phase 3 trial terminated early — PFIZER Amphotericin-B and Voriconazole for Pulmonary Blastomycosis

Phase 3 trial terminated early — PFIZER Dextromethorphan Pediatric Acute Cough Study

Phase 3 trial terminated early — PFIZER Tanezumab In Osteoarthritis Of The Hip Or Knee

Phase 3 trial terminated early — PFIZER Efficacy And Safety Study Of Tanezumab Subcutaneous Administration In Osteoarthr

Phase 3 trial terminated early — ABBOTT Evaluation of Resynchronization Therapy for Heart Failure

Phase 3 trial terminated early — GILEAD Study of Obeldesivir in Children and Adolescents With COVID-19

BITCOIN — speculators net long (+2.5σ vs 52w mean) — contrarian bear signal

HARTFORD INSURANCE GROUP, INC. search volume spiked +100 pts — unusual interest

OSINT: US Tech Momentum ETF Soars 38% YTD, Outpacing S&P 500

Callaway Golf Co search volume spiked +100 pts — unusual interest

SHOPIFY INC. search volume spiked +60 pts — unusual interest

CITIGROUP INC search volume spiked +100 pts — unusual interest

OSINT: Nvidia market cap slips below $5 trillion as shares tumble 4%

EXELON CORP search volume spiked +100 pts — unusual interest

OSINT: Fed December Rate Hike Odds Surge to 77%

OSINT: South Korea's KOSPI plunges 9.99%—largest one‑day fall in history

GAP INC search volume spiked +57 pts — unusual interest

OSINT: Oobit Links USDT to Brazil’s Pix, Unlocking Crypto Payments for 170M Users

HARTFORD INSURANCE GROUP, INC. search volume spiked +100 pts — unusual interest

SHOPIFY INC. search volume spiked +60 pts — unusual interest

CITIGROUP INC search volume spiked +100 pts — unusual interest

Q2-2026: Beat consensus by 44.3% — EPS $-0.06 vs $-0.1078 estimate

Q3-2026: Beat consensus by 103.3% — EPS $0.55 vs $0.2706 estimate

Q4-2026: Beat consensus by 5.5% — EPS $1.16 vs $1.0996 estimate

Q1-2026: Missed consensus by 6.2% — EPS $1.53 vs $1.6309 estimate

Q2-2025: Beat consensus by 7.8% — EPS $1.76 vs $1.6334 estimate

Q2-2025: Missed consensus by 19.3% — EPS $2.37 vs $2.9376 estimate

Q3-2025: Beat consensus by 28.8% — EPS $3.1 vs $2.4072 estimate

Q2-2023: Missed consensus by 29.4% — EPS $-0.04 vs $-0.0309 estimate

Q1-2023: Missed consensus by 21.4% — EPS $-0.05 vs $-0.0412 estimate

Q1-2025: Missed consensus by 1439.9% — EPS $-15.99 vs $1.1934 estimate

Q4-2025: Missed consensus by 6707.4% — EPS $-27.08 vs $-0.3978 estimate

Q2-2025: Missed consensus by 63.4% — EPS $-3.9 vs $-2.3868 estimate

Q3-2025: Missed consensus by 126.9% — EPS $-4.93 vs $-2.1726 estimate

Q2-2024: Beat consensus by 12.9% — EPS $-1.6 vs $-1.836 estimate

Q4-2023: Beat consensus by 10.1% — EPS $-2.2 vs $-2.448 estimate

Q2-2025: Missed consensus by 65.4% — EPS $-6.75 vs $-4.08 estimate

Q3-2025: Missed consensus by 30.7% — EPS $-6.5 vs $-4.9725 estimate

Q4-2025: Missed consensus by 25.3% — EPS $-5.75 vs $-4.59 estimate

Q1-2026: Missed consensus by 95.4% — EPS $-2.99 vs $-1.53 estimate

Q1-2026: Beat consensus by 8.4% — EPS $0.96 vs $0.8856 estimate

Q2-2026: Beat consensus by 9.3% — EPS $1.01 vs $0.9238 estimate

Q4-2025: Beat consensus by 8.2% — EPS $0.89 vs $0.8222 estimate

Q4-2024: Beat consensus by 13.2% — EPS $-10 vs $-11.526 estimate

Q2-2025: Missed consensus by 24.6% — EPS $-12.2 vs $-9.792 estimate

Q1-2025: Missed consensus by 872.2% — EPS $-0.07 vs $-0.0072 estimate

Q4-2024: Missed consensus by 38.9% — EPS $-0.01 vs $-0.0072 estimate

Q4-2025: Beat consensus by 15.3% — EPS $-0.5 vs $-0.5906 estimate

Q3-2025: Beat consensus by 31.3% — EPS $-0.37 vs $-0.5384 estimate

Q2-2025: Beat consensus by 37.6% — EPS $-0.37 vs $-0.593 estimate

Q3-2017: Missed consensus by 17.7% — EPS $53.3 vs $64.741 estimate

Q2-2018: Beat consensus by 12.9% — EPS $62.25 vs $55.146 estimate

Q2-2017: Beat consensus by 7.3% — EPS $58.86 vs $54.843 estimate

Q2-2026: Beat consensus by 8.6% — EPS $1.53 vs $1.4089 estimate

Q1-2027: Beat consensus by 6.2% — EPS $1.55 vs $1.4601 estimate

Q4-2026: Missed consensus by 6.1% — EPS $1.44 vs $1.5328 estimate

Q4-2025: Beat consensus by 86.6% — EPS $-1.11 vs $-8.2852 estimate

Q1-2026: Beat consensus by 38.2% — EPS $-5.58 vs $-9.029 estimate

Q3-2025: Beat consensus by 30.4% — EPS $-5.75 vs $-8.2609 estimate

Q2-2025: Missed consensus by 5.5% — EPS $107.61 vs $113.9187 estimate

Q3-2025: Beat consensus by 32.4% — EPS $-0.03 vs $-0.0444 estimate

Q4-2025: Beat consensus by 24.0% — EPS $-0.05 vs $-0.0658 estimate

Q3-2025: Missed consensus by 146.9% — EPS $-0.09 vs $0.1919 estimate

Q1-2025: Beat consensus by 7.0% — EPS $-0.31 vs $-0.3333 estimate

Q2-2025: Missed consensus by 13.9% — EPS $-0.23 vs $-0.202 estimate

Q3-2024: Missed consensus by 68.4% — EPS $-0.67 vs $-0.3978 estimate

Q4-2024: Beat consensus by 37.0% — EPS $-0.36 vs $-0.5712 estimate

Q1-2025: Missed consensus by 111.2% — EPS $-1.12 vs $-0.5304 estimate

Q3-2025: Beat consensus by 24.8% — EPS $-0.11 vs $-0.1462 estimate

Q4-2025: Beat consensus by 87.9% — EPS $-0.01 vs $-0.0825 estimate

Q2-2025: Beat consensus by 24.0% — EPS $-0.1 vs $-0.1315 estimate

Q1-2026: Beat consensus by 63.1% — EPS $-0.06 vs $-0.1626 estimate

Q1-2026: Beat consensus by 7.3% — EPS $1.56 vs $1.4533 estimate

Q4-2025: Beat consensus by 10.4% — EPS $1.76 vs $1.5948 estimate

Q2-2025: Beat consensus by 21.8% — EPS $1.63 vs $1.3378 estimate

Q4-2025: Beat consensus by 155.8% — EPS $0.32 vs $-0.5739 estimate

Q1-2026: Missed consensus by 28.1% — EPS $-0.71 vs $-0.5541 estimate

Q3-2025: Beat consensus by 20.9% — EPS $1.02 vs $0.8434 estimate

Q2-2025: Missed consensus by 76.8% — EPS $0.19 vs $0.8175 estimate

Q2-2025: Beat consensus by 209.4% — EPS $0.29 vs $-0.2652 estimate

Q4-2025: Missed consensus by 108.3% — EPS $-0.34 vs $-0.1632 estimate

Q3-2025: Beat consensus by 19.0% — EPS $-0.19 vs $-0.2346 estimate

Q4-2025: Beat consensus by 28.0% — EPS $0.21 vs $0.1641 estimate

Q2-2025: Beat consensus by 32.9% — EPS $0.17 vs $0.1279 estimate

Q1-2026: Beat consensus by 14.2% — EPS $0.53 vs $0.4641 estimate

Q2-2025: Missed consensus by 7.3% — EPS $0.4 vs $0.4313 estimate

Q4-2025: Beat consensus by 18.8% — EPS $0.28 vs $0.2357 estimate

Q1-2026: Beat consensus by 38.7% — EPS $0.17 vs $0.1226 estimate

Q3-2025: Beat consensus by 6.5% — EPS $0.2 vs $0.1878 estimate

Q4-2025: Missed consensus by 659.8% — EPS $-0.93 vs $-0.1224 estimate

Q1-2026: Missed consensus by 127.3% — EPS $-0.51 vs $-0.2244 estimate

Q3-2025: Missed consensus by 122.2% — EPS $-0.34 vs $-0.153 estimate

Q1-2026: Beat consensus by 243.1% — EPS $0.07 vs $0.0204 estimate

Q3-2026: Beat consensus by 56.9% — EPS $0.08 vs $0.051 estimate

Q2-2026: Beat consensus by 82.1% — EPS $0.13 vs $0.0714 estimate

Q4-2025: Missed consensus by 100.0% — EPS $0 vs $0.0306 estimate

Q3-2025: Missed consensus by 100.0% — EPS $0 vs $0.0082 estimate

Q2-2025: Missed consensus by 100.0% — EPS $0 vs $0.0069 estimate

Q4-2025: Beat consensus by 191.3% — EPS $0.03 vs $0.0103 estimate

Q1-2026: Missed consensus by 100.0% — EPS $0 vs $0.0103 estimate

Q4-2025: Missed consensus by 8.2% — EPS $2.56 vs $2.7885 estimate

Q1-2026: Missed consensus by 15.8% — EPS $0.73 vs $0.8673 estimate

Q1-2026: Beat consensus by 9.6% — EPS $4.75 vs $4.3336 estimate

Q2-2025: Beat consensus by 6.5% — EPS $3.61 vs $3.3908 estimate

Q3-2025: Missed consensus by 14.2% — EPS $-1.22 vs $-1.0686 estimate

Q4-2025: Missed consensus by 333.0% — EPS $-4.54 vs $-1.0486 estimate

Q2-2025: Missed consensus by 16.7% — EPS $-1.25 vs $-1.071 estimate

Q1-2026: Beat consensus by 9.7% — EPS $-1.46 vs $-1.6177 estimate

Q3-2025: Beat consensus by 21.3% — EPS $0.24 vs $0.1978 estimate

Q1-2026: Beat consensus by 24.1% — EPS $0.12 vs $0.0967 estimate

Q2-2025: Beat consensus by 12.5% — EPS $0.29 vs $0.2577 estimate

Q4-2025: Beat consensus by 10.0% — EPS $0.16 vs $0.1455 estimate

Q3-2025: Missed consensus by 23.1% — EPS $0.41 vs $0.5329 estimate

Q4-2025: Missed consensus by 76.3% — EPS $0.14 vs $0.5916 estimate

Q1-2026: Beat consensus by 31.8% — EPS $1.02 vs $0.7739 estimate

Q4-2025: Missed consensus by 31.3% — EPS $0.97 vs $1.4115 estimate

Q2-2025: Beat consensus by 6.9% — EPS $0.76 vs $0.7112 estimate

Q1-2026: Beat consensus by 6.7% — EPS $2.45 vs $2.2953 estimate

Q4-2026: Beat consensus by 20.7% — EPS $0.102 vs $0.0845 estimate

Q2-2026: Beat consensus by 12.0% — EPS $0.133 vs $0.1188 estimate

Q2-2025: Beat consensus by 37.7% — EPS $0.121 vs $0.0879 estimate

Q4-2025: Beat consensus by 20.1% — EPS $0.082 vs $0.0683 estimate

Q4-2025: Missed consensus by 16.0% — EPS $0.03 vs $0.0357 estimate

china_us_west shipping +13.3% — potential inflation signal

china_us_west shipping +13.3% — potential inflation signal

OSINT: Ukrainian drones strike Russian missile depot in Crimea, trigger big blast

OSINT: US Senate backs bill to halt US military action against Iran

VIX at 19.5: CAUTION territory

OSINT: Ukrainian drones strike Russian missile depot in Crimea, trigger big blast

DXY +0.37% — dollar strength signal

OSINT: US Senate backs bill to halt US military action against Iran

OSINT: Fed December Rate Hike Odds Surge to 77%

OSINT: South Korea's KOSPI plunges 9.99%—largest one‑day fall in history

OSINT: Oobit Links USDT to Brazil’s Pix, Unlocking Crypto Payments for 170M Users

OSINT: US Senate bans Fed CBDC until 2030, protects private stablecoins